Ebola, AI, and Prevention as the Real Cost Cure with Dr. Ashish Jha

Right now the Democratic Republic of the Congo and Uganda are responding to an Ebola outbreak caused by Bundibugyo virus, a strain with no licensed vaccine and no approved treatment. WHO declared it a Public Health Emergency of International Concern on May 17. Dr. Ashish Jha calls it one of the largest Ebola outbreaks on record and believes it spread largely undetected for two to three months before anyone caught it, with confirmed cases turning up hundreds of miles apart. That detection lag lands squarely on hospital leaders. As Dr. Jha puts it, a two week head start on an outbreak headed for your emergency room is the difference between adjusting staffing and guidance in advance and scrambling after patients arrive. His new company, BioRadar, is building what he describes as the biosurveillance system the country needs, something closer to a National Weather Service for biological threats. Dr. Ashish Jha, former White House COVID-19 Response Coordinator, joins Megan Antonelli to connect early detection to the cost and quality levers health system leaders pull every day. The take-home is simple and underused: prevention is not only good medicine, but it is also one of the strongest cost-control strategies in healthcare. Highlights 🦠 On the outbreak: he expects it to get worse before it gets better, and sees a real risk of a traveler carrying it to a major city in Europe or the US. He points to last year's USAID cuts and the WHO withdrawal as reasons we have fewer eyes on the ground than we used to. 🏥 On AI and ambient documentation: his own primary care doctor uses it. The upside is real, the doctor pays more attention. But everything gets documented, the billing codes climb, and as he says, that is not saving the system money. His fix is to reduce complexity first, then deal with prices. 📋 On prior auth: payers and providers share the same frustration. Switzerland, Germany, and the Netherlands run fully private insurance with standardized billing and shared rules on what needs authorization. He argues there is a deal to be cut, less prior auth and faster payments, and everyone comes out ahead except the administrative layer. 💸 On what is coming: aging demographics and a wave of cell and gene therapies, some priced at three to four million dollars per patient, are about to put enormous pressure on budgets. His advice is to get your house in order now, before the crisis forces indiscriminate cuts. 🔬 On value-based care: once a skeptic, now a believer. He wants longer contracts, more two-sided risk over time, and programs that are physician and clinically led rather than another administrative layer. Ashish Jha, MD, MPH, Senior Fellow, Harvard Belfer Center, Co-Founder & CEO, BioRadar Megan Antonelli, Chief Executive Officer, HealthIMPACT Live Subscribe to Digital Health Talks on Apple Podcasts, Spotify, YouTube, or wherever you listen.Learn more about HealthIMPACT Live events, virtual forums, and healthcare leader conversations at healthimpactlive.com.Interested in being a guest, sponsoring, or joining the HealthIMPACT community? Visit healthimpactlive.com/digital-health-talks.